pfizer glp 1 drug Safety worries spur to drop another obesity pill Pfizer scraps daily weight loss

Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation

In this article, we will introduce a GLP-1 receptor agonist, Liraglutide

For example, triple-target agonists like retatrutide are leading multi-target GLP-1 drugs

Preclinical studies have reported that Exendin-4 (Ex-4) and dulaglutide display inhibitory effects on breast cancer, whereas liraglutide presents a trend of increased breast cancer incidence, with the risk ratio rising with prolonged exposure

A review of the long-term efficacy, tolerability, and safety of exenatide once weekly for type 2 diabetes

Concerns also exist about weight regain after discontinuing the medication